Details About Generic Salt ::  Floxurid

Main Medicine Class::    

flox-YOUR-ih-deen

FUDR

Powder for injection

500 mg

Solution for injection

100 mg/mL

Class: Pyrimidine antimetabolite

 Indications Palliative management of GI adenocarcinoma metastatic to the liver administered by continuous regional intra-arterial infusion as long as cancer does not extend beyond area perfused by a single artery.

Tumors of the liver, gallbladder, bile ducts, or kidneys.

 Contraindications Patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.

 Route/Dosage

Hepatic Artery Infusion

ADULTS: Implantable pump Using an implantable pump, administer 0.1 to 0.6 mg/kg/day for 1 to 6 wk, followed by a 14-day rest period between courses. Repeat cycles as long as response continues.

Solid Tumors

ADULTS: IV infusion 0.5 to 1 mg/kg/day for 6 to 15 days or until toxicity occurs.

Interactions

Cimetidine

Cimetidine may increase the bioavailability of floxuridine.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Arterial aneurysm; ischemia; thrombosis; embolism; fibromyositis. DERMATOLOGIC: Localized erythema; alopecia; rash. GI: Nausea and vomiting; diarrhea; enteritis; mucositis; duodenal ulcers; elevated LFTs; hepatic necrosis; hepatic abscesses; intra- and extrahepatic biliary sclerosis; acalculous cholecystitis. HEMATOLOGIC: Bone marrow suppression, nadir at 9 to 14 days; bleeding at the catheter site. OTHER: Fever and malaise; infection of the catheter site.

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy in pediatric patients not established. Extravasation: Local irritation or phlebitis may occur. Refer to your institution-specific protocol. Discontinue use: According to product labeling, promptly discontinue floxuridine if any of the following occur: myocardial ischemia, mucositis or esophagopharyngitis, leukopenia with WBC < 3500/mm³, intractable vomiting, frequent diarrhea, GI ulcer or bleeding, thrombocytopenia with platelets < 100,000/mm³, or hemorrhage from any site. Special risk patients: Use with extreme caution in poor-risk patients who have had high-dose pelvic irradiation or previous use of alkylating agents, who have wide-spread involvement of bone marrow by metastatic tumors, or impaired hepatic or renal function.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Store powder for injection at room temperature. Protect from light. Refrigerate reconstituted solutions. Floxuridine is chemically stable for up to 2 wk under refrigeration. Use preservative-free solutions of floxuridine within 24 hr of reconstitution.
• Reconstitute each vial of powder with 5 mL Sterile Water for Injection for a floxuridine concentration of 100 mg/mL.
• Further dilute the calculated daily dose with 5% Dextrose or 0.9% Sodium Chloride to an appropriate volume for infusion pump delivery.
• For intra-arterial administration, infuse with an appropriate pump to overcome pressure in large arteries.
• Heparin may be added to floxuridine infusions to prevent thrombotic complications.

 Assessment/Interventions

• Careful monitoring of the WBC and platelet count is recommended.

OVERDOSAGE: SIGNS & SYMPTOMS   Nausea, vomiting, diarrhea, GI ulceration and bleeding, bone marrow depression (eg, thrombocytopenia, leukopenia, agranulocytosis)

 Patient/Family Education

• Contraceptive measures are recommended for men and women during therapy.
• Notify healht care provider if chills, nausea, vomiting, unusual bleeding or bruising, yellowing of skin or eyes, abdominal pain, flank or joint pain, or swelling of feet or legs occurs.
• Notify health care provider if the following become pronounced: diarrhea, fever, weakness
• Drink plenty of liquids while taking this drug.
• Inform patients of expected toxic effects, particularly oral manifestations.
• Alert patient to the possibility of alopecia as a result of therapy, and inform patient that alopecia is usually a transient effect.

Medicscientist Drug Facts

 

Drugs Class ::

flox-YOUR-ih-deen

FUDR

Powder for injection

500 mg

Solution for injection

100 mg/mL

Class: Pyrimidine antimetabolite

Indications for Drugs ::

 Indications Palliative management of GI adenocarcinoma metastatic to the liver administered by continuous regional intra-arterial infusion as long as cancer does not extend beyond area perfused by a single artery.

Tumors of the liver, gallbladder, bile ducts, or kidneys.

Drug Dose ::

 Route/Dosage

Hepatic Artery Infusion

ADULTS: Implantable pump Using an implantable pump, administer 0.1 to 0.6 mg/kg/day for 1 to 6 wk, followed by a 14-day rest period between courses. Repeat cycles as long as response continues.

Solid Tumors

ADULTS: IV infusion 0.5 to 1 mg/kg/day for 6 to 15 days or until toxicity occurs.

Contraindication ::

 Contraindications Patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy in pediatric patients not established. Extravasation: Local irritation or phlebitis may occur. Refer to your institution-specific protocol. Discontinue use: According to product labeling, promptly discontinue floxuridine if any of the following occur: myocardial ischemia, mucositis or esophagopharyngitis, leukopenia with WBC < 3500/mm³, intractable vomiting, frequent diarrhea, GI ulcer or bleeding, thrombocytopenia with platelets < 100,000/mm³, or hemorrhage from any site. Special risk patients: Use with extreme caution in poor-risk patients who have had high-dose pelvic irradiation or previous use of alkylating agents, who have wide-spread involvement of bone marrow by metastatic tumors, or impaired hepatic or renal function.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Arterial aneurysm; ischemia; thrombosis; embolism; fibromyositis. DERMATOLOGIC: Localized erythema; alopecia; rash. GI: Nausea and vomiting; diarrhea; enteritis; mucositis; duodenal ulcers; elevated LFTs; hepatic necrosis; hepatic abscesses; intra- and extrahepatic biliary sclerosis; acalculous cholecystitis. HEMATOLOGIC: Bone marrow suppression, nadir at 9 to 14 days; bleeding at the catheter site. OTHER: Fever and malaise; infection of the catheter site.

Drug Mode of Action ::  

flox-YOUR-ih-deen

FUDR

Powder for injection

500 mg

Solution for injection

100 mg/mL

Class: Pyrimidine antimetabolite

Drug Interactions ::

Interactions

Cimetidine

Cimetidine may increase the bioavailability of floxuridine.

Drug Assesment ::

 Assessment/Interventions

• Careful monitoring of the WBC and platelet count is recommended.

OVERDOSAGE: SIGNS & SYMPTOMS   Nausea, vomiting, diarrhea, GI ulceration and bleeding, bone marrow depression (eg, thrombocytopenia, leukopenia, agranulocytosis)

Drug Storage/Management ::

 Administration/Storage

• Store powder for injection at room temperature. Protect from light. Refrigerate reconstituted solutions. Floxuridine is chemically stable for up to 2 wk under refrigeration. Use preservative-free solutions of floxuridine within 24 hr of reconstitution.
• Reconstitute each vial of powder with 5 mL Sterile Water for Injection for a floxuridine concentration of 100 mg/mL.
• Further dilute the calculated daily dose with 5% Dextrose or 0.9% Sodium Chloride to an appropriate volume for infusion pump delivery.
• For intra-arterial administration, infuse with an appropriate pump to overcome pressure in large arteries.
• Heparin may be added to floxuridine infusions to prevent thrombotic complications.

Drug Notes ::

 Patient/Family Education

• Contraceptive measures are recommended for men and women during therapy.
• Notify healht care provider if chills, nausea, vomiting, unusual bleeding or bruising, yellowing of skin or eyes, abdominal pain, flank or joint pain, or swelling of feet or legs occurs.
• Notify health care provider if the following become pronounced: diarrhea, fever, weakness
• Drink plenty of liquids while taking this drug.
• Inform patients of expected toxic effects, particularly oral manifestations.
• Alert patient to the possibility of alopecia as a result of therapy, and inform patient that alopecia is usually a transient effect.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.